Title: Adverse Cutaneous Outbreaks by programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitors: A Review.
Author information :
Maitry Bhardwaj, Mei Nee Chiu, Sangeeta Pilkhwal Sah*
University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014,
India
*Corresponding Author-
Dr. Sangeeta Pilkhwal Sah
Assistant Professor
University Institute of Pharmaceutical Sciences UGC Centre of Advanced Study (UGC-CAS) Panjab University, Chandigarh-160014
Ph.No. +91-9569537674
E-mail:spilkhwal@rediffmail.com
Running head: Cutaneous Adverse Effects caused by PD-1/PD-L1 immune checkpoint inhibitors.
Key Words- Cutaneous eruptions; immunotherapy; immune-related adverse events (irAEs); anti PD-1; pembrolizumab; nivolumab; anti-PD-L1; atezolizumab; avelumab; durvalumab.
Word count – Abstract- 177 Main text- 5222
Table count- 01
Figure legends-
Figure 1: Various adverse cutaneous reactions by programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitors. MHC- major histocompatibility complex; TCR- T-cell receptor.
Figure 1: Classification of cutaneous irAEs into six main categories.
Figure 3: PD-1/PD-L1 induced cutaneous adverse effects with each percentage indicated.
Figure 4: Pathogenesis of PD-1/PD-L1 induces vitiligo.